Products Categories
CAS No.: | 129-18-0 |
---|---|
Name: | Sodium butazolidine |
Molecular Structure: | |
Formula: | C19H20N2NaO2 |
Molecular Weight: | 331.40 |
Synonyms: | 3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, ion(1-), sodium (8CI,9CI);3,5-Pyrazolidinedione,4-butyl-1,2-diphenyl-, sodium deriv. (6CI,7CI);Butazolidine sodium;Diphenyldioxobutylpyrazolidine;GP 26872;Phenylbutazone sodium;Phenylbutazone, sodium salt;Sodium phenylbutazone; |
EINECS: | 204-935-7 |
Density: | 1.063g/mLat 25°C(lit.) |
Boiling Point: | 113°C27mm Hg(lit.) |
Flash Point: | 95 °C |
Appearance: | gray powder complex |
Hazard Symbols: | C |
Risk Codes: | R36/37/38 |
PSA: | 49.99000 |
LogP: | 4.11460 |
Product Name: Sodium butazolidine
CAS Registry Number: 129-18-0
Molecular Formula: C19H20N2NaO2
Molar mass: 331.3635 g/mol
EINECS: 204-935-7
Structure of Sodium butazolidine (CAS NO.129-18-0):
Systematic Name: Sodium 4-butyl-1,2-diphenyl-pyrazolidine-3,5-dione
SMILES: [Na+].O=C3C(CCCC)C(=O)N(c1ccccc1)N3c2ccccc2
InChI: InChI=1/C19H20N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13,17H,2-3,14H2,1H3;/q;+1
InChIKey: BSYZHKCQBROKHA-UHFFFAOYAB
Std. InChI: InChI=1S/C19H20N2O2.Na/c1-2-3-14-17-18(22)20(15-10-6-4-7-11-15)21(19(17)23)16-12-8-5-9-13-16;/h4-13,17H,2-3,14H2,1H3;/q;+1
Std. InChIKey: BSYZHKCQBROKHA-UHFFFAOYSA-N
Sodium butazolidine (CAS NO.129-18-0) can be used for antipyretic analgesics for the treatment of rheumatic and rheumatoid arthritis and gout, etc.
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
mouse | LD50 | intraperitoneal | 169mg/kg (169mg/kg) | Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970. | |
mouse | LD50 | intravenous | 94mg/kg (94mg/kg) | Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958. | |
mouse | LD50 | oral | 476mg/kg (476mg/kg) | Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 314, 1970. | |
mouse | LD50 | subcutaneous | 257mg/kg (257mg/kg) | Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 63, Pg. 43, 1967. | |
rabbit | LD50 | intravenous | 146mg/kg (146mg/kg) | Schweizerische Medizinische Wochenschrift. Vol. 84, Pg. 1315, 1954. | |
rat | LD50 | intravenous | 113mg/kg (113mg/kg) | Farmaco, Edizione Scientifica. Vol. 13, Pg. 922, 1958. | |
rat | LD50 | oral | 855mg/kg (855mg/kg) | Indian Journal of Physiology and Pharmacology. Vol. 5, Pg. 113, 1961. | |
rat | LD50 | subcutaneous | 310mg/kg (310mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) | Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 229, 1958. |
women | LDLo | oral | 16mg/kg/D (16mg/kg) | LUNGS, THORAX, OR RESPIRATION: STRUCTURAL OR FUNCTIONAL CHANGE IN TRACHEA OR BRONCHI BLOOD: AGRANULOCYTOSIS SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" | Annals of Internal Medicine. Vol. 39, Pg. 1096, 1953. |
A human poison by ingestion. Human systemic effects by ingestion: respiratory system damage, agranulocytosis, and dermatitis. An experimental poison via subcutaneous, intravenous, and intraperitoneal routes. An anti-inflammatory drug. When heated to decomposition it emits toxic fumes of NOx and Na2O.
Sodium butazolidine (CAS NO.129-18-0) also can be called 4-Butyl-1,2-diphenylpyrazolidine-3,5-dione, sodium salt and 3,5-Pyrazolidinedione, 4-butyl-1,2-diphenyl-, monosodium salt .